MAX BIOPHARMA, INC
- SANTA MONICA, CA 90404-3637
- maxbiopharma.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM expired
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expired
The registration expired on Nov 11, 2026. Federal awards require an active SAM.gov registration (FAR 4.1102), so confirm renewal before proposing this company as a team member.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About MAX BIOPHARMA, INC
- Headquarters
- SANTA MONICA, CA 90404-3637
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEINZ8XY5DKRAD3
- CAGE67CG2
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 10 awards
- Total awarded
- $8,501,205
- By phase
- SBIR Phase I: 5
- SBIR Phase II: 5
- By agency
- Department of Health and Human Services: 10
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2023: 1
- 2022: 2
- 2021: 1
- 2020: 1
- 2018: 1
- 2016: 2
- 2014: 1
- 2013: 1
Awards (most recent first)
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $1,786,691
May 1, 2023 – Apr 30, 2025
Solicitation PA22-176 (2022) · Topic 300
An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $318,089
Aug 10, 2022 – Jul 31, 2023
Solicitation PA21-259 (2021) · Topic NHLBI
Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $320,724
May 23, 2022 – Apr 30, 2023
Solicitation PA21-259 (2021) · Topic NHLBI
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $1,707,540
Sep 1, 2021 – Aug 31, 2023
- Direct to Phase II
Solicitation PA20-260 (2020) · Topic NIAMS
Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $223,696
Aug 21, 2020 – Jun 30, 2021
Solicitation PA19-272 (2019) · Topic 300
Preclinical Development of Oxy200 for the Treatment of Osteoporosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $1,950,018
Sep 30, 2018 – May 31, 2020
Solicitation PA17-302 (2017) · Topic NIA
Design and synthesis of bone selective osteogenic oxysterol bisphosphonate analogues
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $998,650
Sep 15, 2016 – Aug 31, 2018
Solicitation PA14-071 (2014) · Topic NIA
Synthesis of bone selective osteogenic oxysterols
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $899,267
Mar 17, 2016 – Feb 28, 2018
Solicitation PA14-071 (2014) · Topic NIAMS
Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analog
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $149,342
Solicitation PA13-234 (2014) · Topic NIAMS · Research partner: Stub
Investigational Safety and Toxicity Studies of Subcutaneous COG1410 for Alzheimer
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $147,188
Solicitation PA12-088 (2013) · Topic NIAMS · Research partner: Stub
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Primary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with MAX BIOPHARMA, INC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.